Jan 2, 2017
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) Is About To Release Some Game Changing Data
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) Is About To Release Some Game Changing Data
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) kicked off a phase III trial back in 2015, investigating its lead candidate, Trabodenoson, in glaucoma patients. The trial completed enrollment back in August, and is set to read out on topline this month. The company has had a pretty flat year from a valuation perspective, ranging between the $6 and $10, but the Trabodenoson release is likely going to…
View On WordPress